XML 265 R64.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Other Disclosures - Collaborations and Technology Licenses (Details) € in Millions, kr in Millions, $ in Millions |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 10, 2020 USD ($) item | Oct. 31, 2020 | Jul. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) Option | Jul. 31, 2018 USD ($) item | Dec. 31, 2017 item | Jun. 30, 2021 USD ($) item | Dec. 31, 2021 USD ($) Option item | Dec. 31, 2020 USD ($) | Dec. 31, 2012 | Dec. 31, 2021 DKK (kr) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 DKK (kr) | Dec. 31, 2019 EUR (€) | Aug. 31, 2015 USD ($)
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments accounted for using equity method | kr |  |  |  |  |  |  |  |  |  |  | kr 371 |  | kr 1,081 |  |
Janssen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty obligation expiration term after first sale of product |  |  |  |  |  |  |  | 13 years |  |  |  |  |  |  |
Milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  | $ 191.0 |  |  |
Upfront payment |  |  |  |  |  |  |  | $ 3.5 |  |  |  |  |  |  |
Number of additional programs | item |  |  |  |  |  |  |  | 10 |  |  |  |  |  |  |
Initial payments received |  |  |  |  |  |  |  | $ 2.0 |  |  |  |  |  |  |
Number of license exercised | item |  |  |  |  |  |  |  | 14 |  |  |  |  |  |  |
Number of license options remaining to be exercised | Option |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |
Novartis (Arzaerra/Ofatumumab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage for non-cancer treatment |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |
Lump sum payment received |  |  |  |  |  |  |  |  | $ 30.0 |  |  |  |  |  |
Seagen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost and profit sharing ratio |  | 50 |  |  |  |  |  |  |  |  |  |  |  |  |
AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional candidates selected | item | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 750.0 |  | $ 750.0 |  |  |  |  |  |  |  |  |  |  |  |
Ratio of share of profits before income taxes | 50 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations | item | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of delivery license programs | item | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of discover research and development cost responsible by the entity | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioNTech |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional candidates selected | item |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
Upfront fee paid |  |  |  |  |  |  |  | $ 10.0 |  |  |  |  |  |  |
Novo Nordisk A/S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of potential target pair combinations | item |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |
Options to obtain commercial licenses | item |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |
CureVac |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fee payable |  |  |  | $ 10.0 |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, Development, Regulatory and commercial milestone payment |  |  |  | $ 280.0 |  |  |  |  |  |  |  |  |  |  |
Options to obtain commercial licenses | Option |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |
Option exercisable period |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |
Investments accounted for using equity method |  |  |  |  |  |  |  |  |  |  | 318 |  | kr 1,067 | € 20 |
Percentage of investment in common shares |  |  |  |  |  |  |  | 35.00% |  |  |  |  |  |  |
Bolt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments accounted for using equity method |  |  |  |  |  |  | $ 15.0 |  |  |  | kr 26 |  |  |  |
Upfront fee paid |  |  |  |  |  |  | $ 10.0 |  |  |  |  |  |  |  |
Threshold number of clinical candidates evaluated for development | item |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |
Co-developed development cost split ratio |  |  |  |  |  |  | 50 |  |  |  |  |  |  |  |
Milestone payments receivable |  |  |  |  |  |  | $ 285.0 |  |  |  |  |  |  |  |
Immatics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development regulatory and commercial milestone payments to be made |  |  |  |  | $ 550.0 |  |  |  |  |  |  |  |  |  |
Number of proprietary targets of license | item |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |
Number of additional proprietary targets of license | item |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Upfront fee paid |  |  |  |  | $ 54.0 |  |  |  |  |  |  |  |  |  |
Bottom of range [member] | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty percentage |  |  |  |  |  |  |  |  |  | 12.00% |  |  |  |  |
Bottom of range [member] | CureVac |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, Development, Regulatory and commercial milestone payment |  |  |  | $ 275.0 |  |  |  |  |  |  |  |  |  |  |
Top of range [member] | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty percentage |  |  |  |  |  |  |  |  |  | 20.00% |  |  |  |  |
Milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  | $ 175.0 |  |  |
Top of range [member] | Novo Nordisk A/S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, Development, Regulatory and commercial milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250.0
Top of range [member] | CureVac |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, Development, Regulatory and commercial milestone payment |  |  |  | $ 368.0 |  |  |  |  |  |  |  |  |  |  |
Development Regulatory and Sales Milestone | Top of range [member] | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables | $ 3,150.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Countries Outside United States and Japan | Bottom of range [member] | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percent on sales | 22.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Countries Outside United States and Japan | Top of range [member] | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percent on sales | 26.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Development and Commercial Success Across all Three Programs | Development Regulatory and Sales Milestone | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables | $ 1,150.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Success of all Four Next Generation Antibody Product Candidates Developed | Development Regulatory and Sales Milestone | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables | $ 2,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The ratio in which the development cost will be split if a candidate is co-developed under the collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationAgreementCoDevelopedDevelopmentCostSplitRatio
Namespace Prefix: | gmab_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of development regulatory and commercial milestone payments to be made by the company under the agreement. + References No definition available. + Details
Name: | gmab_CollaborationAgreementDevelopmentRegulatoryAndCommercialMilestonePaymentsToBeMade
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of milestone payment receivable under the collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationAgreementMilestonePaymentsReceivable
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of collaboration agreements, development regulatory and commercial milestone payment. + References No definition available. + Details
Name: | gmab_CollaborationAgreementsDevelopmentRegulatoryAndCommercialMilestonePayment
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the cost and profit sharing ratio. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementCostAndProfitSharingRatio
Namespace Prefix: | gmab_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash in flow from initial payments received. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementInitialPaymentReceived
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment receivable under an collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementMilestonePaymentReceivable
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of royalties of worldwide net sales ofatumumab for the treatment of non-cancer under the agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementNonCancerTreatmentRoyaltyPercentageOnWorldWideNetSales
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of lump sum payment received under an collaboration agreement for lost potential royalties. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementPaymentReceivedForLostRoyalties
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term from first sale of the product after which obligation to pay royalties under the agreement will expire. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementRoyaltyObligationExpirationTermAfterFirstSaleOfProduct
Namespace Prefix: | gmab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of tiered royalty under the collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementTieredRoyaltyPercentage
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront fee payment made under an collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementUpfrontFeePaid
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront fee payable under an collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementUpfrontFeePayable
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of discover research and development cost responsible by the entity. + References No definition available. + Details
Name: | gmab_DiscoverResearchAndDevelopmentCostResponsibilityPercent
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents number of additional candidates selected for development. + References No definition available. + Details
Name: | gmab_NumberOfAdditionalCandidatesSelected
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional programs party to the agreement is entitled to work on. + References No definition available. + Details
Name: | gmab_NumberOfAdditionalProgramEntitledToBeWorked
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional proprietary targets of license. + References No definition available. + Details
Name: | gmab_NumberOfAdditionalProprietaryTargetsOfLicense
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of delivery license programs. + References No definition available. + Details
Name: | gmab_NumberOfDeliveryLicenses
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of license exercised under the agreement. + References No definition available. + Details
Name: | gmab_NumberOfLicenseOptionsExercised
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of license options remaining to be exercised under the agreement. + References No definition available. + Details
Name: | gmab_NumberOfOptionsRemainingToBeExercised
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of performance obligations. + References No definition available. + Details
Name: | gmab_NumberOfPerformanceObligations
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of potential target pair combinations. + References No definition available. + Details
Name: | gmab_NumberOfPotentialTargetPairCombinations
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of proprietary targets of license. + References No definition available. + Details
Name: | gmab_NumberOfProprietaryTargetsOfLicense
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The period for which the entity has the option to obtain commercial license. + References No definition available. + Details
Name: | gmab_OptionExercisablePeriodCommercialLicense
Namespace Prefix: | gmab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of options to obtain commercial license. + References No definition available. + Details
Name: | gmab_OptionsToObtainCommercialLicense
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of investment in common shares. + References No definition available. + Details
Name: | gmab_PercentageOfInvestmentInCommonShares
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The ratio of share of profits before income taxes. + References No definition available. + Details
Name: | gmab_RatioOfShareOfProfitsBeforeIncomeTaxes
Namespace Prefix: | gmab_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of royalties on sales. + References No definition available. + Details
Name: | gmab_RoyaltyPercentSales
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Na + References No definition available. + Details
Name: | gmab_ShareholdingsByBoardOfDirectorsAndExecutiveManagementLineItems
Namespace Prefix: | gmab_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Threshold number of clinical candidates evaluated for development. + References No definition available. + Details
Name: | gmab_ThresholdNumberOfClinicalCandidatesEvaluatedForDevelopment
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash in flow from upfront milestone payments. + References No definition available. + Details
Name: | gmab_UpfrontMilestonePaymentReceived
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 24 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph B16 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B16&doctype=Appendix&subtype=B -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 54 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 54 -Subparagraph h -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 78 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_TradeAndOtherReceivables
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovoNordiskSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_ImmaticsBiotechnologiesGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_TypesOfRevenuesAxis=gmab_DevelopmentRegulatoryAndSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=gmab_CountriesOutsideUnitedStatesAndJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gmab_ClinicalDevelopmentAndCommercialSuccessAcrossAllThreeProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gmab_SuccessOfAllFourNextGenerationAntibodyProductCandidatesDevelopedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |